Hepatitis Monthly

Published by: Kowsar

Substitution Rtq267h of Hepatitis B Virus Increases the Weight of Replication and Lamivudine Resistance

Bo Qin 1 , 2 , * , Bo Zhang 2 , Xiaodong Zhang 3 , Tingting He 1 , Wenying Xu 1 , Lijun Fu 1 and Chunyu Tu 1
Authors Information
1 Shaoxing Centre for Disease Control and Prevention, Shaoxing, China
2 State Key Lab of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
3 College of Life Science, Shaoxing University, Shaoxing, China
Article information
  • Hepatitis Monthly: October 01, 2013, 13 (10); e12160
  • Published Online: October 1, 2013
  • Article Type: Research Article
  • Received: May 11, 2013
  • Revised: July 7, 2013
  • Accepted: August 27, 2013
  • DOI: 10.5812/hepatmon.12160

To Cite: Qin B, Zhang B, Zhang X, He T, Xu W, et al. Substitution Rtq267h of Hepatitis B Virus Increases the Weight of Replication and Lamivudine Resistance, Hepat Mon. 2013 ;13(10):e12160. doi: 10.5812/hepatmon.12160.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Vietheer PTK, Netter HJ, Sozzi T, Bartholomeusz A. Failure of the Lamivudine-Resistant rtM204I Hepatitis B Virus Mutants To Efficiently Support Hepatitis Delta Virus Secretion. Failure Lamivudine Resistant rtM204I Hepatitis B Virus Mutants Efficiently Support Hepatitis Delta Virus Secretion. 2005; 79(10): 6570-73
  • 2. Gao W, Hu J. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol. 2007; 81(12): 6164-74[DOI][PubMed]
  • 3. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004; 350(11): 1118-29[DOI][PubMed]
  • 4. Le Pogam S, Yuan TT, Sahu GK, Chatterjee S, Shih C. Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein. J Virol. 2000; 74(19): 9099-105[PubMed]
  • 5. Thursz M, Njie R, Lemoine M. Global eradication of hepatitis B--feasible or fallacy? . J Virol. 2012; 9(9): 492-94
  • 6. Pallier C, Castera L, Soulier A, Hezode C, Nordmann P, Dhumeaux D, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 2006; 80(2): 643-53[DOI][PubMed]
  • 7. Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res. 2006; 71(2-3): 206-15[DOI][PubMed]
  • 8. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. J Virol. 2009; 137(5): 1593-608
  • 9. Lin X, Yuan ZH, Wu L, Ding JP, Wen YM. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency. J Virol. 2001; 75(23): 11827-33
  • 10. Lanford RE, Kim YH, Lee H, Notvall L, Beames B. Mapping of the hepatitis B virus reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and by protein-protein interaction. J Virol. 1999; 73(3): 1885-93
  • 11. Qin B, Budeus B, Cao L, Wu C, Wang Y, Zhang X, et al. The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. Antiviral Res. 2013; 97(2): 93-100
  • 12. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol. 2002; 97(7): 1618-28[DOI][PubMed]
  • 13. Bo Qin TH, Zhaohui H, Guoshao P, Chunyu T, Mengji L, Xinwen C. Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir . Chinese S Bull. 2013; 58(15): 1760-66
  • 14. Qin B, He T, Chen Z, Xu W, Pan G, Tu C. A novel method for the analysis of drug-resistant phenotypes of hepatitis B virus. Int J Mol Med. 2013; 31(4): 975-81[DOI][PubMed]
  • 15. Grunenberg R, Banik N, Kruger J. [Alanine aminotransferase (ALAT, GPT): a reevaluation of exclusion limits for blood donors]. Infusionsther Transfusionsmed. 1995; 22(3): 145-51[PubMed]
  • 16. Qiu J, Qin B, Rayner S, Wu CC, Pei RJ, Xu S, et al. Novel evidence suggests Hepatitis B virus surface proteins participate in regulation of HBV genome replication. Virologica Sinica. Vir Sinica. 2011; 26(2): 131-38
  • 17. Meng Z, Xu Y, Wu J, Tian Y, Kemper T, Bleekmann B, et al. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. Journal of virological methods. J Virol Me. 2008; 15(1-2): 27-33
  • 18. Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepato. 2004; 41(4): 659-66
  • 19. Cai WJ, Yin L, Zhou D, Cao WJ, Zheng WW, Sheng L, et al. Association between polymorphisms of the E-selectin gene, hepatitis B virus DNA copies and preS1 antigen in patients with chronic hepatitis B infection. Molecular medicine reports. Mol Med Rep. 2012; 6(2): 1069-74
  • 20. Zaaijer HL, van Hemert FJ, Koppelman MH, Lukashov VV. Independent evolution of overlapping polymerase and surface protein genes of hepatitis B virus. J Gen Virol. 2007; 88: 2137-43[DOI][PubMed]
  • 21. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepato. 1998; 27(6): 1670-77
  • 22. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis. 2001; 1(4): 232-41
  • 23. Preiss S, Littlejohn M, Angus P, Thompson A, Desmond P, Lewin SR, et al. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology. 2008; 48(3): 741-9[DOI][PubMed]
  • 24. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005; 10(6): 727-34[PubMed]
  • 25. Bo Q, RongJuan P, TingTing H, ZhaoHui H, GuoShao P, ChunYu T, et al. Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir. Chinese Science Bulletin. Chinese S Bull. 2013; 58(15): 1760-66
  • 26. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antiviral Ther. 2004; 9(3): 353-66
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments